¼¼°èÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ½ÃÀå
Bioprocess Analyzers
»óǰÄÚµå : 1774001
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 464 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 40¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 22¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 10.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 40¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼Ò¸ðǰ ¹× ¾×¼¼¼­¸®´Â CAGR 12.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 25¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 5¾ï 9,280¸¸ ´Þ·¯, Áß±¹Àº CAGR 14.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ½ÃÀåÀº 2024³â¿¡ 5¾ï 9,280¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8¾ï 3,440¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 14.7%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 7.4%¿Í 9.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â°¡ ¹ÙÀÌ¿À Á¦¾à »ê¾÷¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â´Â ¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ß¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ´ÜŬ·ÐÇ×ü, ¹é½Å, À¯ÀüÀÚ Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¹× ÃÖÀûÈ­¸¦ À§ÇÑ Ã·´Ü ºÐ¼® µµ±¸ÀÇ »ç¿ëÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼® Àåºñ´Â pH, ¿ëÁ¸ »ê¼Ò, ¼¼Æ÷ ¹Ðµµ, ´ë»ç»ê¹° ³óµµ, ¿µ¾ç¼Ò ¼öÁذú °°Àº ÆÄ¶ó¹ÌÅÍ¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© »ý¹°ÇÐÀû Á¦Á¦ÀÇ Àϰü¼º°ú ǰÁúÀ» º¸ÀåÇϸç, FDA ¹× EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº °øÁ¤ ºÐ¼® ±â¼ú(PAT) ÇÁ·¹ÀÓ¿öÅ©¸¦ Áß¿ä½ÃÇϰí ÀÖÀ¸¸ç, Á¦¾à»ç ¹× Á¦¾àȸ»ç ¹× »ý¸í°øÇÐ ±â¾÷ Àü¹Ý¿¡ °ÉÃÄ ¹ÙÀÌ¿À °øÁ¤ ºÐ¼® ±â±âÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ¿Í ¿¬¼Ó »ý»ê °øÁ¤ÀÇ µîÀåÀ¸·Î ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â´Â ³ôÀº »ý»ê¼º°ú ¾ö°ÝÇÑ Ç°Áú °ü¸® Ç¥ÁØÀ» ÁؼöÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±âÀÇ È¿À²¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±âÀÇ ÁøÈ­´Â ¼¾¼­ ±â¼ú, ÀÚµ¿È­ ¹× ÀΰøÁö´É(AI)ÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ±¤ÇÐ ¹× Àü±âÈ­ÇÐ ¼¾¼­ÀÇ Çõ½ÅÀº °øÁ¤ ¸ð´ÏÅ͸µÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀ» Å©°Ô Çâ»ó½Ã۰í, ¹èÄ¡ °£ ÆíÂ÷¸¦ ÁÙÀ̸ç, ¹Ýº¹¼ºÀ» ³ôÀ̰í, AI ±â¹Ý ºÐ¼® ¹× ±â°è ÇнÀ ¾Ë°í¸®ÁòÀÌ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â¿¡ ÅëÇÕµÇ¾î ¿¹Ãø À¯Áöº¸¼ö, ½Ç½Ã°£ Á¶Á¤, °øÁ¤ ÃÖÀûÈ­¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ºÐ¼® ÀåºñÀÇ ¼ÒÇüÈ­·Î ÀÎÇØ ÈÞ´ë¿ë ¹× ÀζóÀÎ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ °³¹ßÀÌ ¿ëÀÌÇØÁ® ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ È¿À²¼º°ú È®À强ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÷´Ü µ¥ÀÌÅÍ ºÐ¼®°ú Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº ½Ç½Ã°£ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¿ø°Ý ¾×¼¼½º¸¦ Á¦°øÇÏ°í ½ÇÇè½Ç°ú Á¦Á¶ ½Ã¼³ °£ÀÇ ¿øÈ°ÇÑ Çù¾÷À» °¡´ÉÇϰÔÇÔÀ¸·Î½á ¹ÙÀÌ¿À Á¦¾à »ê¾÷¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¿î¿µ ºñ¿ëÀ» Àý°¨ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Áß¿äÇÑ Ä¡·áÁ¦ÀÇ ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇϰí ÀÖÀ¸¸ç, ±â¼ú ¹ßÀüÀº ½ÃÀå È®´ëÀÇ ÁÖ¿ä ÃËÁøÁ¦ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±âÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ½ÃÀå µ¿ÇâÀº ¹«¾ùÀΰ¡?

¸î °¡Áö ÁÖ¿ä µ¿ÇâÀÌ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ½ÃÀåÀÇ ¼ºÀå ±Ëµµ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À Á¦Á¶ ºÐ¾ß¿¡¼­ ÀÚµ¿È­ µµÀÔÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´Ù¾çÇÑ ÆÄ¶ó¹ÌÅ͸¦ ¿øÈ°ÇÏ°Ô ¸ð´ÏÅ͸µÇϰí Á¦¾îÇÒ ¼ö ÀÖ´Â ÅëÇÕ ÇÁ·Î¼¼½º ºÐ¼® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à »ê¾÷ÀÇ ¿¬¼Ó °øÁ¤À¸·ÎÀÇ ÀüȯÀº ÀϰüµÈ Á¦Ç° ǰÁú°ú È¿À²¼ºÀ» º¸ÀåÇÏ´Â ½Ç½Ã°£ ºÐ¼® ±â´É¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× ¼¼Æ÷ Ä¡·áÁ¦ ½ÃÀåÀÇ È®´ë·Î ¾ö°ÝÇÑ Ç°Áú °ü¸® Á¶Ä¡ÀÇ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÷´Ü ¹ÙÀÌ¿À °øÁ¤ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÅÈï±¹¿¡¼­´Â ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ´ë±Ô¸ð ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ÀÌ´Â ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â Á¦Á¶¾÷ü¿¡ À¯¸®ÇÑ ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾÷°è ¼±µµ±â¾÷°ú ÇÐ°è ¹× ¿¬±¸±â°üÀÇ Çù·ÂÀ¸·Î ÀÚµ¿È­, ´ÙÇ׸ñ °ËÃâ ±â´É, µ¥ÀÌÅÍ ºÐ¼® ±â´ÉÀ» °®Ãá Â÷¼¼´ë ºÐ¼®±â °³¹ßÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â ½ÃÀåÀÇ ¼ºÀåÀº ¹ÙÀÌ¿ÀÀǾàǰ ¼ö¿ä Áõ°¡, ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­, ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. »õ·Î¿î À¯ÀüÀÚ Ä¡·áÁ¦, ¹ÙÀÌ¿À½Ã¹Ð·¯, ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦ °³¹ß µî ¹ÙÀÌ¿ÀÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ È®´ë·Î ÀÎÇØ Á¤È®Çϰí È¿À²ÀûÀÎ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¸ð´ÏÅ͸µ µµ±¸ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ±â¼úÀÇ Ã¤ÅÃÀÌ È®´ëµÇ¸é¼­ »ý»êÀ» ÃÖÀûÈ­ÇÏ°í ¿À¿° À§ÇèÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ½Ç½Ã°£ ºÐ¼®¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °øÁ¤ °ËÁõ ¹× ǰÁú °ü¸®¿¡ ´ëÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ °­È­µÊ¿¡ µû¶ó Á¦¾à»çµéÀº ±ÔÁ¤ Áؼö¸¦ À§ÇØ Ã·´Ü ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼® Àåºñ¿¡ ÅõÀÚÇÒ ¼ö¹Û¿¡ ¾ø´Â »óȲÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º¿¡ AI, ºòµ¥ÀÌÅÍ, IoT¸¦ ÅëÇÕÇÏ¿© °øÁ¤ Á¦¾î ¹× ¿¹Ãø ºÐ¼®À» °­È­ÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ »ê¾÷À» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ ¼Ö·ç¼ÇÀÇ ÃßÁøÀ¸·Î ¹ÙÀÌ¿À Á¦¾à»çµéÀº ÃÖ÷´Ü ¹ÙÀÌ¿À °øÁ¤ ¸ð´ÏÅ͸µ ±â¼úÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ßÀÇ °æÀïÀÌ Ä¡¿­ÇØÁü¿¡ µû¶ó Á¦Á¶¾÷üµéÀº Á¤È®¼º, È¿À²¼º ¹× ±ÔÁ¤ Áؼö¸¦ ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ºÐ¼®±â´Â Çö´ë ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¼Ò¸ðǰ ¹× ºÎ¼Óǰ, ±â±â), ºÐ¼® À¯Çü(³óµµ °ËÃâ, ±âÁú ºÐ¼®, ´ë»ç¹° ºÐ¼®), ¿ëµµ(Ç×»ýÁ¦, ÀçÁ¶ÇÕ ´Ü¹éÁú, ¹ÙÀÌ¿À½Ã¹Ð·¯, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷, CRO ¹× CMO, ¿¬±¸ ¹× Çмú±â°ü, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bioprocess Analyzers Market to Reach US$4.0 Billion by 2030

The global market for Bioprocess Analyzers estimated at US$2.2 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Consumables & Accessories, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.8 Million While China is Forecast to Grow at 14.7% CAGR

The Bioprocess Analyzers market in the U.S. is estimated at US$592.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$834.4 Million by the year 2030 trailing a CAGR of 14.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Bioprocess Analyzers Market - Key Trends & Drivers Summarized

Why Are Bioprocess Analyzers Gaining Importance in the Biopharmaceutical Industry?

Bioprocess analyzers are playing a pivotal role in the biopharmaceutical sector, where the demand for precision and efficiency in bioproduction is at an all-time high. The increasing complexity of biologics, including monoclonal antibodies, vaccines, and gene therapies, has necessitated the use of advanced analytical tools for real-time monitoring and optimization of bioprocesses. These analyzers provide critical insights into parameters such as pH, dissolved oxygen, cell density, metabolite concentrations, and nutrient levels, ensuring the consistency and quality of biologics. Regulatory agencies such as the FDA and EMA are emphasizing process analytical technology (PAT) frameworks, further driving the adoption of bioprocess analyzers across pharmaceutical and biotechnology firms. Additionally, the rise of single-use bioreactors and continuous manufacturing processes has amplified the need for real-time monitoring solutions, making bioprocess analyzers indispensable for achieving high productivity and compliance with stringent quality control standards.

How Are Technological Advancements Enhancing the Efficiency of Bioprocess Analyzers?

The evolution of bioprocess analyzers is closely tied to rapid advancements in sensor technology, automation, and artificial intelligence (AI). Innovations in optical and electrochemical sensors have significantly improved the accuracy and reliability of process monitoring, reducing batch-to-batch variability and enhancing reproducibility. AI-driven analytics and machine learning algorithms are now being integrated into bioprocess analyzers, enabling predictive maintenance, real-time adjustments, and process optimization. Furthermore, miniaturization of analytical devices has facilitated the development of portable and inline monitoring solutions, making bioprocessing more efficient and scalable. Advanced data analytics and cloud-based platforms are also revolutionizing the biopharma industry by providing remote access to real-time bioprocess data, enabling seamless collaboration between research labs and manufacturing facilities. These innovations are not only reducing operational costs but are also expediting time-to-market for critical therapeutics, making technological advancements a key driver of market expansion.

What Are the Key Market Trends Driving the Growth of Bioprocess Analyzers?

Several key trends are influencing the growth trajectory of the bioprocess analyzers market. The increasing adoption of automation in biomanufacturing is leading to a greater demand for integrated process analytical solutions that can seamlessly monitor and control various parameters. The biopharmaceutical industry’s shift toward continuous processing is also driving the need for real-time analytical capabilities, ensuring consistent product quality and efficiency. Moreover, the expansion of biosimilar and cell therapy markets has heightened the importance of stringent quality control measures, further bolstering demand for advanced bioprocess monitoring solutions. Emerging economies, particularly in Asia-Pacific, are witnessing significant investments in biopharmaceutical manufacturing infrastructure, creating lucrative opportunities for bioprocess analyzer manufacturers. Additionally, collaborations between industry leaders and academic research institutions are fostering the development of next-generation bioprocess analyzers, with enhanced automation, multi-analyte detection capabilities, and improved data analytics.

What Are the Key Drivers Fueling the Growth of the Bioprocess Analyzers Market?

The growth in the bioprocess analyzers market is driven by several factors, including rising demand for biologics, increasing regulatory scrutiny, and rapid technological advancements. The expanding biopharmaceutical pipeline, including the development of novel gene therapies, biosimilars, and cell-based treatments, has intensified the need for precise and efficient bioprocess monitoring tools. The growing adoption of single-use bioprocessing technologies has further increased reliance on real-time analytics to optimize production and minimize contamination risks. Additionally, heightened regulatory requirements for process validation and quality control are compelling pharmaceutical companies to invest in advanced bioprocess analyzers to ensure compliance. The integration of AI, big data, and IoT in bioprocessing is also transforming the industry, enabling enhanced process control and predictive analytics. Moreover, the push for cost-effective and scalable biologic manufacturing solutions is driving biopharma companies to implement state-of-the-art bioprocess monitoring technologies. As competition in the biologics sector intensifies, manufacturers are prioritizing precision, efficiency, and compliance, making bioprocess analyzers a crucial component of modern biopharmaceutical production.

SCOPE OF STUDY:

The report analyzes the Bioprocess Analyzers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Consumables and Accessories, Instruments); Analysis Type (Concentration Detection, Substrate Analysis, Metabolite Analysis); Application (Antibiotics Application, Recombinant Proteins Application, Biosimilars Application, Other Applications); End-Use (Biopharmaceutical Companies End-Use, CROs and CMOs End-Use, Research and Academic Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â